Fig. 5: Bcl-2 and Bcl-xL mRNA are part of the IMP3 complex. | Cell Death & Disease

Fig. 5: Bcl-2 and Bcl-xL mRNA are part of the IMP3 complex.

From: A novel tumour enhancer function of Insulin-like growth factor II mRNA-binding protein 3 in colorectal cancer

Fig. 5: Bcl-2 and Bcl-xL mRNA are part of the IMP3 complex.The alternative text for this image may have been generated using AI.

A Left, representative Western blot of IMP3 immunoprecipitation from HCT-116 cells, β-actin is used as a negative control. Input (1:10) of the total protein extracts, IMP3 immunoprecipitation (IP: IMP3), and mock immunoprecipitation (IP: IgG). Right, relative quantification of IMP3-mRNAs enrichment by RT-qPCR in IMP3 immunoprecipitation/total protein extracted from HCT-116 cells. β-actin mRNAs were used as control (mean ± SEM; IP: IMP3 versus IP: IgG *P ≤ 0.05; n = 3). B Bcl-xL and Bcl-2 mRNA levels detected by Real time PCR in HCT-116 cells left untreated (Unst) or transfected with CTR or IMP3 siRNA for 30 h. Unst and CTR siRNA-treated cells versus IMP3 siRNA-transfected cells, **p ≤ 0.01; n = 3). C Representative Western blot showing IMP3, Bcl-xL, Bcl-2 and β-actin in HCT-116 cells were left untreated (Unst) or transfected with control or IMP3 siRNA for 36 h. Right, quantification of IMP3, Bcl-xL and Bcl-2 proteins in HCT-116 cells as measured by densitometry of Western blot (values are expressed in arbitrary units (a.u.), mean ± SD, n = 4; IMP3: Unst and CTR siRNA-treated cells versus IMP3 siRNA-transfected cells, **p ≤ 0.01; n = 3).

Back to article page